Fig. 4

The effect of AGE-Tf on ROS in human podocytes. (A), (B), and (C): Comparison of ROS levels of human podocytes among different groups. AGE-Tf Advanced glycated end-products modified transferrin, NC Negative control, 0mMGlu-AGE-Tf Glucose concentration is 0 mM when preparing AGE-Tf, 5.6mMGlu-AGE-Tf Glucose concentration is 5.6 mM when preparing AGE-Tf, 11.1mMGlu-AGE-Tf Glucose concentration is 11.1 mM when preparing AGE-Tf, 33.3mMGlu-AGE-Tf Glucose concentration is 33.3 mM when preparing AGE-Tf, DFO deferoxamine mesylate, RAP receptor-for-advanced-glycation-end-productsantagonist peptide, Fer-1 Ferrostatin-1. *p < 0.05;**p < 0.01; ***p < 0.001; ****p < 0.0001.